Jenne Kyle
EVP, Chf GL Pdt Str Ofcr
Jenne Kyle has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Apr 17, 2026.
On the most recent filing, Jenne Kyle is listed as EVP, Chf GL Pdt Str Ofcr at IONIS PHARMACEUTICALS INC. Inside the rolling window, Jenne Kyle reported no open-market purchases and 3 open-market sales totaling $3.3M in IONS. The largest disclosed transaction in the window is a sale of 37,277 IONS shares on Mar 10, 2026, worth $2.8M.
Companies traded
Other insiders at IONS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Jenne Kyle made?
Jenne Kyle has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company since 2026.
Which companies does Jenne Kyle trade?
Jenne Kyle has filed SEC Form 4 disclosures for 1 company, including IONS.
When was Jenne Kyle's most recent SEC Form 4 filing?
Jenne Kyle's most recent SEC Form 4 filing on Tracefour is dated Apr 17, 2026.
What is Jenne Kyle's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Jenne Kyle is listed as EVP, Chf GL Pdt Str Ofcr.
What is Jenne Kyle's total buy and sell value in the current window?
Inside the rolling retention window, Jenne Kyle bought $0 and sold $3.3M based on SEC Form 4 filings.
What was Jenne Kyle's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 37,277 IONS shares on 2026-03-10, worth $2.8M, per SEC Form 4 filings.